JPWO2020142725A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020142725A5 JPWO2020142725A5 JP2021538996A JP2021538996A JPWO2020142725A5 JP WO2020142725 A5 JPWO2020142725 A5 JP WO2020142725A5 JP 2021538996 A JP2021538996 A JP 2021538996A JP 2021538996 A JP2021538996 A JP 2021538996A JP WO2020142725 A5 JPWO2020142725 A5 JP WO2020142725A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- item
- lnp
- virus
- copies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 51
- 150000002632 lipids Chemical class 0.000 claims description 50
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 36
- 230000001225 therapeutic effect Effects 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 25
- -1 CCL4 Proteins 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 101000941029 Homo sapiens Endoplasmic reticulum junction formation protein lunapark Proteins 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 14
- 239000002679 microRNA Substances 0.000 claims description 13
- 108700011259 MicroRNAs Proteins 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 241000709687 Coxsackievirus Species 0.000 claims description 10
- 241000837158 Senecavirus A Species 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 244000309459 oncolytic virus Species 0.000 claims description 10
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 9
- 102000006240 membrane receptors Human genes 0.000 claims description 9
- 108091070946 miR-128 stem-loop Proteins 0.000 claims description 9
- 241000114864 ssRNA viruses Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000037978 Immune checkpoint receptors Human genes 0.000 claims description 6
- 108091008028 Immune checkpoint receptors Proteins 0.000 claims description 6
- 108091007780 MiR-122 Proteins 0.000 claims description 6
- 108091027966 Mir-137 Proteins 0.000 claims description 6
- 108091027766 Mir-143 Proteins 0.000 claims description 6
- 241000709664 Picornaviridae Species 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 6
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 6
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 6
- 108091031479 miR-204 stem-loop Proteins 0.000 claims description 6
- 108091032382 miR-204-1 stem-loop Proteins 0.000 claims description 6
- 108091085803 miR-204-2 stem-loop Proteins 0.000 claims description 6
- 108091089766 miR-204-3 stem-loop Proteins 0.000 claims description 6
- 108091073500 miR-204-4 stem-loop Proteins 0.000 claims description 6
- 108091053626 miR-204-5 stem-loop Proteins 0.000 claims description 6
- 108091035328 miR-217 stem-loop Proteins 0.000 claims description 6
- 108091039135 miR-217-1 stem-loop Proteins 0.000 claims description 6
- 108091029206 miR-217-2 stem-loop Proteins 0.000 claims description 6
- 108091063841 miR-219 stem-loop Proteins 0.000 claims description 6
- 108091070636 miR-219a stem-loop Proteins 0.000 claims description 6
- 108091028066 Mir-126 Proteins 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 230000002601 intratumoral effect Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 4
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 3
- 241000709700 Coxsackievirus A9 Species 0.000 claims description 3
- 241000709675 Coxsackievirus B3 Species 0.000 claims description 3
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 3
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims description 3
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000003810 Interleukin-18 Human genes 0.000 claims description 3
- 108090000171 Interleukin-18 Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims description 3
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 230000001524 infective effect Effects 0.000 claims description 2
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 30
- 229920001223 polyethylene glycol Polymers 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 11
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 10
- 108020004511 Recombinant DNA Proteins 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- JEJLGIQLPYYGEE-UHFFFAOYSA-N 1,2-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 210000001808 exosome Anatomy 0.000 description 5
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000010954 inorganic particle Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002071 nanotube Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100007584 Entamoeba histolytica CPNP gene Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241001372913 Maraba virus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024143254A JP2024167285A (ja) | 2019-01-04 | 2024-08-23 | カプセル化ポリヌクレオチド及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788504P | 2019-01-04 | 2019-01-04 | |
| US62/788,504 | 2019-01-04 | ||
| US201962895135P | 2019-09-03 | 2019-09-03 | |
| US62/895,135 | 2019-09-03 | ||
| PCT/US2020/012237 WO2020142725A1 (en) | 2019-01-04 | 2020-01-03 | Encapsulated rna polynucleotides and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024143254A Division JP2024167285A (ja) | 2019-01-04 | 2024-08-23 | カプセル化ポリヌクレオチド及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516318A JP2022516318A (ja) | 2022-02-25 |
| JPWO2020142725A5 true JPWO2020142725A5 (ru) | 2023-01-19 |
Family
ID=71406664
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538996A Pending JP2022516318A (ja) | 2019-01-04 | 2020-01-03 | カプセル化ポリヌクレオチド及び使用方法 |
| JP2024143254A Pending JP2024167285A (ja) | 2019-01-04 | 2024-08-23 | カプセル化ポリヌクレオチド及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024143254A Pending JP2024167285A (ja) | 2019-01-04 | 2024-08-23 | カプセル化ポリヌクレオチド及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220117902A1 (ru) |
| EP (1) | EP3906039A4 (ru) |
| JP (2) | JP2022516318A (ru) |
| KR (1) | KR20210113260A (ru) |
| CN (1) | CN113453699A (ru) |
| AU (1) | AU2020204989A1 (ru) |
| BR (1) | BR112021013155A2 (ru) |
| CA (1) | CA3124524A1 (ru) |
| IL (1) | IL284433A (ru) |
| MX (1) | MX2021008146A (ru) |
| SG (1) | SG11202107282VA (ru) |
| TW (1) | TW202043480A (ru) |
| WO (1) | WO2020142725A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE066181T2 (hu) | 2018-10-09 | 2024-07-28 | Univ British Columbia | Szerves oldószerektõl és detergensektõl mentes transzfekció-kompetens vezikulumokat tartalmazó készítmények és rendszerek, és az azokkal kapcsolatos eljárások |
| US20220267799A1 (en) * | 2019-08-05 | 2022-08-25 | Virogin Biotech Canada Ltd | Genetically modified enterovirus vectors |
| CA3204244A1 (en) * | 2021-01-06 | 2022-07-14 | Lorena Lerner | Encapsulated rna polynucleotides and methods of use |
| AU2022210419A1 (en) * | 2021-01-19 | 2023-07-20 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| AU2022227607A1 (en) * | 2021-02-23 | 2023-08-24 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| US20240358652A1 (en) * | 2021-08-17 | 2024-10-31 | Monash University | Lipid nanoparticle formulations |
| CN113980915B (zh) * | 2021-11-04 | 2023-07-07 | 江苏省人民医院（南京医科大学第一附属医院） | 一种新型的表达cxcl10的复制型溶瘤腺病毒和应用 |
| FR3129833B1 (fr) | 2021-12-03 | 2024-09-06 | Univ Claude Bernard Lyon | Nanoparticules pour la liberation d’acides nucleiques |
| CN118785924A (zh) * | 2022-03-04 | 2024-10-15 | 益杰立科(上海)生物科技有限公司 | 靶向眼部细胞的递送系统和方法 |
| WO2024009316A1 (en) * | 2022-07-04 | 2024-01-11 | Bharat Biotech International Limited | Cationic lipid based composition, formulation and use for nucleic acid vaccine delivery and preparation thereof |
| CN115227674B (zh) * | 2022-08-05 | 2023-07-04 | 武汉滨会生物科技股份有限公司 | 包封的溶瘤病毒遗传物质及其应用 |
| WO2024086810A1 (en) * | 2022-10-21 | 2024-04-25 | Georgia Tech Research Corporation | Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof |
| WO2024226779A1 (en) * | 2023-04-26 | 2024-10-31 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638318B2 (en) * | 2003-09-26 | 2009-12-29 | Norvartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| US20080160031A1 (en) * | 2005-01-17 | 2008-07-03 | Viralytics Limited | Method and Composition for Treatment of Neoplasms |
| US10000757B2 (en) * | 2005-05-27 | 2018-06-19 | Ospedale San Raffaele S.R.L. | Gene vector |
| EP2125032A4 (en) * | 2007-02-20 | 2011-02-23 | Mayo Foundation | CANCER TREATMENT WITH VIRAL NUCLEIC ACID |
| JP2012509272A (ja) * | 2008-11-17 | 2012-04-19 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 核酸送達系のための放出性カチオン脂質 |
| WO2013073480A1 (ja) * | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| MX2014014196A (es) * | 2012-05-23 | 2015-08-14 | Univ Ohio State | Composiciones de nanoparticulas de albumina recubiertas con lipido y metodos de preparacion y metodo de uso de las mismas. |
| WO2014171526A1 (ja) * | 2013-04-17 | 2014-10-23 | 国立大学法人九州大学 | 遺伝子改変コクサッキーウイルス |
| WO2016118724A1 (en) * | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| PT3408382T (pt) * | 2016-01-27 | 2022-06-27 | Oncorus Inc | Vetores virais oncolíticos e seus usos |
| BR112019000015A2 (pt) * | 2016-06-30 | 2019-04-24 | Oncorus, Inc. | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos |
| JP7306653B2 (ja) * | 2017-03-17 | 2023-07-11 | 国立大学法人千葉大学 | 構造強化されたＳ－ＴｕＤを用いた新規がん治療法 |
| EP3594329A4 (en) * | 2017-04-19 | 2021-02-24 | The University Of Tokyo | GENETICALLY MODIFIED COXSACKIE VIRUS, AND PHARMACEUTICAL COMPOSITION |
| US11033622B2 (en) * | 2017-05-25 | 2021-06-15 | Leidos, Inc. | PD-1 and CTLA-4 dual inhibitor peptides |
| RU2020106730A (ru) * | 2017-07-14 | 2021-08-16 | Онкорус, Инк. | Инкапсулированные полинуклеотиды и способы их применения |
-
2020
- 2020-01-03 KR KR1020217024261A patent/KR20210113260A/ko active Search and Examination
- 2020-01-03 WO PCT/US2020/012237 patent/WO2020142725A1/en unknown
- 2020-01-03 US US17/418,465 patent/US20220117902A1/en active Pending
- 2020-01-03 CN CN202080014652.4A patent/CN113453699A/zh active Pending
- 2020-01-03 CA CA3124524A patent/CA3124524A1/en active Pending
- 2020-01-03 AU AU2020204989A patent/AU2020204989A1/en active Pending
- 2020-01-03 MX MX2021008146A patent/MX2021008146A/es unknown
- 2020-01-03 EP EP20735846.6A patent/EP3906039A4/en active Pending
- 2020-01-03 JP JP2021538996A patent/JP2022516318A/ja active Pending
- 2020-01-03 BR BR112021013155-8A patent/BR112021013155A2/pt unknown
- 2020-01-03 TW TW109100228A patent/TW202043480A/zh unknown
- 2020-01-03 SG SG11202107282VA patent/SG11202107282VA/en unknown
-
2021
- 2021-06-28 IL IL284433A patent/IL284433A/en unknown
-
2024
- 2024-08-23 JP JP2024143254A patent/JP2024167285A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qin et al. | mRNA-based therapeutics: powerful and versatile tools to combat diseases | |
| JPWO2020142725A5 (ru) | ||
| Han et al. | Nanomaterials for therapeutic RNA delivery | |
| Wang et al. | mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications | |
| Young et al. | Clinical delivery of circular RNA: lessons learned from RNA drug development | |
| Feng et al. | RNA therapeutics-research and clinical advancements | |
| Kauffman et al. | Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo | |
| Bates et al. | Carbon nanotubes as vectors for gene therapy: past achievements, present challenges and future goals | |
| JP2020530778A5 (ru) | ||
| CN112153985A (zh) | 用于颗粒制剂的防冻剂 | |
| Tyagi et al. | Exploiting nanotechnology for the development of microRNA-based cancer therapeutics | |
| Wang et al. | Nanoparticle-based delivery system for application of siRNA in vivo | |
| Ferdows et al. | RNA cancer nanomedicine: nanotechnology-mediated RNA therapy | |
| JP2024167285A (ja) | カプセル化ポリヌクレオチド及び使用方法 | |
| Kumari et al. | The emerging potential of siRNA nanotherapeutics in treatment of arthritis | |
| Koli et al. | SiRNA-based therapies for pulmonary diseases | |
| Khan et al. | Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery | |
| Ma et al. | Advanced gene therapy system for the treatment of solid tumour: A review | |
| Yu et al. | The clinical progress and challenges of mRNA vaccines | |
| Arruda et al. | Innovative nonviral vectors for small-interfering RNA delivery and therapy | |
| JPWO2022150485A5 (ru) | ||
| Sun et al. | Supramolecular assembly models of siRNA delivery systems | |
| Obeid et al. | Targeting siRNAs in cancer drug delivery | |
| RU2021123104A (ru) | Инкапсулированные полинуклеотиды рнк и способы их применения | |
| Ray et al. | Therapeutic targeting non-coding RNAs |